BCYC
Bicycle Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$340.87M
P/E Ratio
—
EPS
$-3.16
Beta
1.65
52W High
$9.55
52W Low
$4.24
50-Day MA
$5.40
200-Day MA
$6.88
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Fundamentals
| Revenue (TTM) | $72.59M |
| Gross Profit (TTM) | $-156.50M |
| EBITDA | $-236.44M |
| Operating Margin | -42.80% |
| Return on Equity | -31.20% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $1.05 |
| Book Value | $8.79 |
| Price-to-Book | 0.58 |
| Price-to-Sales (TTM) | 4.70 |
| EV/Revenue | 21.22 |
| EV/EBITDA | -2.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1193.00% |
| Shares Outstanding | $50.27M |
| Float | $1.88M |
| % Insiders | 4.43% |
| % Institutions | 75.84% |
Analyst Ratings
Consensus ($12.67 target)
2
Strong Buy6
Buy4
HoldData last updated: 4/7/2026